Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Mutational Characterisation and Tracking Disease Progression Using Circulating Cell-Free Tumor DNA in Multiple Myeloma Patients

Sridurga Mithraprabhu, PhD, Tiffany Khong, BSc, PhD, Malarmathy Ramachandran, Annie W.S. Chow, Daniela Klarica, RN, Laura Mai, Stephanie Walsh, David Broemeling, Andre Marziali, Matthew Wiggin, Jay Hocking, MD PhDstudent, Anna Kalff, MBBS, FRACP, FRCPA, Brian G.M. Durie, MD, Andrew Spencer

Blood (2016) 128 (22): 3280.

https://doi.org/10.1182/blood.V128.22.3280.3280

Published: 2016

Journal Articles

Roar: A Phase Ib Trial of Oral Azacitidine (CC-486) in Combination with Lenalidomide and Dexamethasone (Rd) for Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma Who Have Failed a Prior Lenalidomide-Containing Regimen

Anna Kalff, MBBS, FRACP, FRCPA, Kate Reed, Tiffany T. Khong, PhD, Sridurga Mithraprabhu, PhD, Malarmathy Ramachandran, John Reynolds, Krystal Bergin, Anjan Thakurta, PhD, Maria Wang, PhD, Andrew Spencer, Roberto Guzman, Suzana Cuoto, Yan Ren, MD

Blood (2016) 128 (22): 2121.

https://doi.org/10.1182/blood.V128.22.2121.2121

Published: 2016

Journal Articles

High Risk Multiple Myeloma: Better Outcomes with Upfront Tandem Autologous- Non-Myelo Ablative Allogeneic Stem Cell Transplantation Compared to Upfront Autologous Stem Cell Transplantation

Anish Puliyayil Nair, MD DM, FRACP, Cindy Lee, FRACP, FRCPA, Anna Kalff, MBBS, FRACP, FRCPA, Patricia A. Walker, MBBS, FRACP, FRCPA, Krystal Bergin, Jay Hocking, MD PhDstudent, Sue Morgan, FRACP, FRCPA, MBBS, Daniela Klarica, RN, Jenny Muirhead, Andrew Spencer, Oi Lin Lee, Noemi Horvath, MB, ChB, FRACP, FRCPA

Blood (2016) 128 (22): 4684.

https://doi.org/10.1182/blood.V128.22.4684.4684

Published: 2016

Journal Articles

A 2-Stage Phase II Study of Panobinostat Consolidation in Multiple Myeloma (MM) Patients with < CR Following Single High-Dose Chemotherapy (HDT) Conditioned Autologous Stem Cell Transplantation (ASCT) As Part of First Line Therapy

Anna Kalff, MBBS, FRACP, FRCPA, Sridurga Mithraprabhu, PhD, Tiffany T. Khong, PhD, Malarmathy Ramachandran, Kate Reed, Hang Quach, MBBS (Hons), FRACP, FRCPA, MD, Patricia A. Walker, MBBS, FRACP, FRCPA, Krystal Bergin, Andrew Spencer

Blood (2016) 128 (22): 4515.

https://doi.org/10.1182/blood.V128.22.4515.4515

Published: 2016

Journal Articles

Autologous Stem Cell Transplantation (ASCT) Followed By Outpatient-Based Non-Myeloblative Allogeneic (NMA) Stem Cell Transplantation (Tandem Auto-Allo) for Biologically Adverse Multiple Myeloma (MM). a Single Centre Experience from Australia

Anish Puliyayil Nair, MD DM, Patricia A. Walker, MBBS, FRACP, FRCPA, Anna Kalff, MBBS, FRACP, FRCPA, Krystal Bergin, MBBS, Sharon Avery, MBBS (Hons), FRACP, FRCPA, David J. Curtis, MD, PhD, Sushrut S. Patil, FRACP, FRCPA, Jenny Muirhead, Tongted Phomoonna, Daniela Klarica, RN, Andrew Spencer

Blood (2015) 126 (23): 2030.

https://doi.org/10.1182/blood.V126.23.2030.2030

Published: 2015

Journal Articles

Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments

Anna Kalff, MBBS, FRACP, FRCPA, Nola Kennedy, Patricia A. Walker, MBBS, FRACP, FRCPA, Tiffany T. Khong, BSc, PhD, Anthony Schwarer, MD, Andrew W. Roberts, MBBS, PhD, Philip Campbell, MBBS, FRACP, FRCPA, Robin Filshie, PhD FRACP, Angela Smiley, Malgorzata Gorniak, Marion Black, Nicole Jenkins, Geoffrey Raines, Andrew Spencer, MBBS FRACP FRCPA MD

Blood (2014) 124 (21): 2103.

https://doi.org/10.1182/blood.V124.21.2103.2103

Published: 2014

Journal Articles

Leopard: A Phase II Study Of Post Autologous Stem Cell Transplantation (ASCT) Maintenance Lenalidomide and Prednisolone For Myeloma (MM), Incorporating Minimal Residual Disease (MRD) Assessments

Anna Kalff, MBBS, FRACP, FRCPA, Nola Kennedy, Patricia A. Walker, MBBS, FRACP, FRCPA, Marion Black, Odette Youdell, Malgorzata Gorniak, Tiffany T. Khong, BSc, PhD, Lona Estifo, Angela Smiley, Anthony P. Schwarer, MD, Andrew W. Roberts, MBBS, PhD, Philip Campbell, MBBS, FRACP, FRCPA, Robin Flishie, Andrew Spencer, MD

Blood (2013) 122 (21): 3223.

https://doi.org/10.1182/blood.V122.21.3223.3223

Published: 2013

Journal Articles

Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma Is Feasible, Efficacious and Associated With Low Transplant-Related Morbidity and Mortality

Philip Campbell, MBBS, FRACP, FRCPA, Patricia A. Walker, MBBS, FRACP, FRCPA, Sharon Avery, MBBS, Sushrut S. Patil, FRACP, FRCPA, David J. Curtis, M.D., Ph.D., Anthony P. Schwarer, MD, Andrew H Wei, MBBS, PhD, Anna Kalff, MBBS, FRACP, FRCPA, Jenny Muirhead, Andrew Spencer, MD

Blood (2013) 122 (21): 2128.

https://doi.org/10.1182/blood.V122.21.2128.2128

Published: 2013

Journal Articles

Incidence and Kinetics Of Full Donor Chimerism and The Impact Of Minimal Residual Disease Status Following Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma

Philip Campbell, MBBS, FRACP, FRCPA, Tongted Das, David Kipp, Patricia A. Walker, MBBS, FRACP, FRCPA, Jenny Muirhead, Sharon Avery, MBBS, Sushrut S. Patil, FRACP, FRCPA, David J. Curtis, M.D., Ph.D., Anthony P. Schwarer, MD, Anna Kalff, MBBS, FRACP, FRCPA, Andrew Spencer, MD

Blood (2013) 122 (21): 2129.

https://doi.org/10.1182/blood.V122.21.2129.2129

Published: 2013

Journal Articles

Thalidomide Consolidation Post Autologous Stem Cell Transplant (ASCT) For Multiple Myeloma (MM) Is Cost-Effective With Durable Survival Benefit At 5 Years Post Randomisation: Final Analysis Of The ALLG MM6 Study

Anna Kalff, MBBS, FRACP, FRCPA, Nola Kennedy, Angela Smiley, H. Miles Prince, MBBS, FRACP, FRCPA, MD, Andrew W. Roberts, MBBS, PhD, Kenneth F Bradstock, MBBS, PhD, FRACP, FRCPA, Richard De Abreu Lourenco, Andrew Spencer, MD

Blood (2013) 122 (21): 537.

https://doi.org/10.1182/blood.V122.21.537.537

Published: 2013

NARROW

Mutational Characterisation and Tracking Disease Progression Using Circulating Cell-Free Tumor DNA in Multiple Myeloma Patients

Roar: A Phase Ib Trial of Oral Azacitidine (CC-486) in Combination with Lenalidomide and Dexamethasone (Rd) for Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma Who Have Failed a Prior Lenalidomide-Containing Regimen

High Risk Multiple Myeloma: Better Outcomes with Upfront Tandem Autologous- Non-Myelo Ablative Allogeneic Stem Cell Transplantation Compared to Upfront Autologous Stem Cell Transplantation

A 2-Stage Phase II Study of Panobinostat Consolidation in Multiple Myeloma (MM) Patients with < CR Following Single High-Dose Chemotherapy (HDT) Conditioned Autologous Stem Cell Transplantation (ASCT) As Part of First Line Therapy

Autologous Stem Cell Transplantation (ASCT) Followed By Outpatient-Based Non-Myeloblative Allogeneic (NMA) Stem Cell Transplantation (Tandem Auto-Allo) for Biologically Adverse Multiple Myeloma (MM). a Single Centre Experience from Australia

Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments

Leopard: A Phase II Study Of Post Autologous Stem Cell Transplantation (ASCT) Maintenance Lenalidomide and Prednisolone For Myeloma (MM), Incorporating Minimal Residual Disease (MRD) Assessments

Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma Is Feasible, Efficacious and Associated With Low Transplant-Related Morbidity and Mortality

Incidence and Kinetics Of Full Donor Chimerism and The Impact Of Minimal Residual Disease Status Following Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma

Thalidomide Consolidation Post Autologous Stem Cell Transplant (ASCT) For Multiple Myeloma (MM) Is Cost-Effective With Durable Survival Benefit At 5 Years Post Randomisation: Final Analysis Of The ALLG MM6 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only